38 completed. 38 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 38 | Completed 38 |
| Phase 2 | 16 | Completed 16 |
Follow Impulsive Behavior: new trials by email Literature Review of Impulsive Behavior trials Research Report on Impulsive Behavior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Placebo, Auvelity - Addiction, Opioid Use | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | 18 | 2023-09-18 | 2026-08-19 |
| Boost Study 31380 (mHealth) mHealth - Addiction | Phase 1 | Completed | NXTech | 43 | 2022-04-18 | 2024-12-18 |
| Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160) Combination Product: Naltrexone - Opiod Use Disorder | Phase 1 | Completed | Delpor, Inc. | 10 | 2022-03-22 | 2025-02-13 |
| A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers 18-MC Compound - Addiction | Phase 1 | Completed | Definium Therapeutics US, Inc. | 108 | 2020-04-14 | 2022-01-05 |
| Social Decision Making in Parkinson's Disease Pramipexole, Placebo - Parkinson Disease | Phase 1 | Completed | Vanderbilt University Medical Center | 18 | 2019-12-03 | 2023-10-18 |
| Effects of Random Nicotine Delivery on Smoking Cessation Nicotine Film - Smoking Cessation, Cigarette Smoking | Phase 1 / Phase 2 | Completed | Milton S. Hershey Medical Center | 45 | 2019-03-12 | 2021-01-22 |
| The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers ANS-6637 - Opiod Use Disorder | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 26 | 2019-03-01 | 2020-08-03 |
| Effects of Nicotine in Tobacco Smokers Cigarette 1, Cigarette 2, Patch 1 - Smoking, Tobacco, Smoking (Tobacco) Addiction | Phase 1 | Completed | University of Southern California | 221 | 2019-02-04 | 2023-07-13 |
| Use of Intranasal Oxytocin During Detoxification of Crack Cocaine Oxytocin nasal spray, placebo nasal spray, Conventional Inpatient Treatment - Cocaine Withdrawal, Cocaine Smoking | Phase 1 / Phase 2 | Completed | Pontificia Universidade Católica do Rio Grande do Sul | 84 | 2018-09-17 | 2026-09-28 |
| Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants, Placebo - Attention Deficit Hyperactivity Disorder | Phase 1 / Phase 2 | Completed | Oregon Health and Science University | 135 | 2018-04-23 | 2023-02-08 |
| Oxytocin HIV Meth Study Oxytocin, Placebo - Amphetamine Use Disorders | Phase 1 | Completed | University of California, San Francisco | 48 | 2017-01-01 | 2019-03-05 |
| Cocaine Opioid Oxytocin Option - Limited Oxytocin, Placebo - Opioid Use Disorder, Cocaine Use Disorder | Phase 1 | Completed | University of California, San Francisco | 30 | 2014-07-01 | 2019-05-21 |
| Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance Placebo, Hydromorphone, Buprenorphine - Opioid Dependence, Pain | Phase 1 | Completed | Johns Hopkins University | 132 | 2013-08-01 | 2017-09-11 |
| To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers GSK1521498, Naltrexone (NTX), Placebo - Alcoholism | Phase 1 | Completed | GlaxoSmithKline | 56 | 2012-12-12 | 2017-05-10 |
| Impulsivity and Stimulant Administration cocaine hydrochloride, methylphenidate - Cocaine Dependence, Impulsivity | Phase 1 | Completed | Yale University | 29 | 2012-11-01 | 2023-02-16 |
| Yoga for Pain and Opioid Dependence Yoga, Educational Counseling - Chronic Pain, Opioid Addiction | Phase 1 / Phase 2 | Completed | Yale University | 8 | 2012-04-01 | 2015-09-25 |
| Clinical Efficacy of Atomoxetine for Methamphetamine Dependence Atomoxetine, placebo - Methamphetamine Dependence | Phase 1 / Phase 2 | Completed | University of Arkansas | 20 | 2012-04-01 | 2017-02-09 |
| A Cognitive Behavioral Therapy-Based Text Messaging Intervention for Methamphetamine Dependence Text messages - Methamphetamine Dependence | Phase 1 | Completed | New Leaf Treatment Center | 25 | 2012-04-01 | 2013-07-10 |
| Evaluation of Transdermal Nicotine Replacement Therapy (NRT) Activity Through Metabolic Induction Nicabate 21mg transdermal NRT - Smoking, Addiction | Phase 1 | Completed | The Queen Elizabeth Hospital | 52 | 2011-07-01 | 2017-04-10 |
| Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction transcranial Direct Current Stimulation - Cocaine Addiction, Cocaine-related Disorder | Phase 1 / Phase 2 | Completed | Federal University of Espirito Santo | 20 | 2011-06-01 | 2014-01-30 |
Showing 20 of 38. Sign in to see all of them.
Behavior, Addictive (32) · Substance-Related Disorders (14) · Cocaine-Related Disorders (7) · Opioid-Related Disorders (6) · Alcoholism (3) · Smoking (3) · Obesity (2) · Pain (2) · Attention Deficit Disorder with Hyperactivity (1) · Behavior (1) · Bipolar Disorder (1) · Chronic Pain (1) · Cigarette Smoking (1) · Cocaine Smoking (1)
Behavior (37) · Compulsive Behavior (33) · Mental Disorders (27) · Chemically-Induced Disorders (26) · Substance-Related Disorders (12) · Pathological Conditions, Signs and Symptoms (7) · Narcotic-Related Disorders (6) · Signs and Symptoms (5) · Neurologic Manifestations (4) · Alcohol-Related Disorders (3) · Nervous System Diseases (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3) · Overnutrition (3)
Cognitive Behavioral Therapy (3) · Buprenorphine (2) · Buprenorphine, Naloxone Drug Combination (2) · Cocaine (2) · N-((3,5-difluoro-3'-(1H-1,2,4-triazol-3-yl)-4-biphenylyl)methyl)-2,3-dihydro-1H-inden-2-amine (2) · Oxytocin (2) · Transcranial Direct Current Stimulation (2) · 18-methoxycoronaridine (1) · ANS-6637 (1) · Acamprosate (1) · Amino Acids (1) · Amphetamine (1) · Antioxidants (1) · Atomoxetine Hydrochloride (1) · Atrial Natriuretic Factor (1)
GlaxoSmithKline (5) · Yale University (3) · Johns Hopkins University (2) · University of California, San Francisco (2) · Vanderbilt University Medical Center (2) · Virginia Commonwealth University (2) · Baylor College of Medicine (1) · Dartmouth-Hitchcock Medical Center (1) · Definium Therapeutics US, Inc. (1) · Delpor, Inc. (1) · Federal University of Espirito Santo (1) · Jazz Pharmaceuticals (1) · Medical University of South Carolina (1) · Milton S. Hershey Medical Center (1) · NXTech (1)
United States (27) · United Kingdom (4) · Australia (3) · Brazil (2) · Canada (2)
Aaron T. Beck, MD (1) · Adam M Leventhal, PhD (1) · Ahmed Elkashef, M.D. (1) · Alex Choo, MD (1) · Alexis Vien, MD (1) · Alison Oliveto, PhD (1) · Annie Umbricht, M.D. (1) · Brian Smith, MBBS, PhD (1) · Bryan K. Tolliver, M.D., Ph.D. (1) · Chris Stauffer, MD (1) · Christopher S Stauffer, MD (1) · Christopher Sciamanna, MD (1) · D. Andrew Tompkins, M.D., M.H.S. (1) · Declan T Barry, Ph.D. (1)
PMID 21671456, PMID 23144826, PMID 24139147, PMID 24647726, PMID 25414797, PMID 30791944, PMID 31304887, PMID 31763491, PMID 33884617, PMID 34303786, PMID 34697392, PMID 35770861, PMID 38551365, PMID 40772654, PMID 41776068
5UG1DA050207 (1), K01DA027750 (1), K23DA016574 (1), K23DA029609 (1), K24DA000435 (1), P20MH071905 (1), P50DA009262 (1), P50DA027841 (1), R01DA025764 (1), R01DA027065 (1), R21DA020583 (1), R21DA038775 (1), R25MH071584 (1), R43DA051270 (1)